Thursday, September 29, 2016

The eighth annual Invest For Kids Chicago conference is coming up soon on October 26th, 2016. It will feature presentations from elite investment managers in concise 15 minute presentations in order to benefit underprivileged kids in the Chicago area. You can register for the conference here.

Per Google Finance, Transocean is "an international provider of offshore contract drilling services for oil and gas wells. The Company's primary business is to contract its drilling rigs, related equipment and work crews primarily on a day rate basis to drill oil and gas wells. The Company operates through the contract drilling services segment. The Company specializes in technically demanding regions of the global offshore drilling business with a particular focus on deepwater and harsh environment drilling services. Its mobile offshore drilling fleet consists of floaters and high-specification jackups used in support of offshore drilling activities and offshore support services across the world. The Company owns or has partial ownership interests in and operates over 60 mobile offshore drilling , including approximately 30 ultra‑deepwater floaters, over seven harsh environment floaters, over five deepwater floaters, over 10 midwater floaters and approximately 10 high-specification jackups."

Wednesday, September 28, 2016

Julian Robertson of legendary hedge fund Tiger Management appeared on Bloomberg late yesterday in an interview with Tom Keene. In it, they touched on a myriad of topics, including the hedge fund industry, which Robertson said was facing the most challenging time ever. He also said a bubble is brewing in financial assets.

Here's a quick summary with the video below:

- While interest rates aren't negative in the US yet, thinks it's tragic they're down this far

- Says Janet Yellen's not willing to see the American public take pain

- Robertson said negative and near-zero rates from central banks have sped up borrowing at low costs and money is flowing into financial assets. Thinks bubble in equities and when it bursts, will spread to real estate.

- "I would tell them (investors) in my opinion, there's going to be chaos created by the negative and low interest rates."

- Thinks investors should have at least some money allocated to hedge funds, so that they can truly be hedged and have some protection

- That said, thinks some great companies are undervalued, cited healthcare, biotech, and technology stocks specifically. "A company like Celgene is very reasonably priced. The Google's, those type things, Microsoft. They're available at very reasonable multiples."

- Specifically called out bonds as stretched with all the bond-buying programs. Yields at record lows has forced prices to levels that aren't sustainable

- Thinks China will come out with a strong program against hydrocarbons

- Feels there's already a lot of regulation in the hedge fund industry, especially compared to what it used to be. But says that's normal as an industry grows.

- "It's the most difficult time I've ever seen in the (hedge fund) business. Because there are a lot of people who are squeezing shorts and they make a business of doing that. Furthermore, I don't quite know how the quants work, but I think they have a way of squeezing shorts that is very tough too. At any rate, I think it's tougher to be a hedge fund investor than ever before. Hedge funds ordinarily don't outperform the markets except when the markets go down. But right now it's a very difficult time for them."

- Says you make every effort to avoid any areas where insider trading could be possible: "It's very difficult to determine whether something is an excellent job of research or is in fact inside information."

- On the UK: "I think London is gonna be durable, but this gonna be tough on the UK. I think it's gonna be very tough."

- On Europe: "I'm reasonably pessimistic on Europe. But I think the immediate problem is probably rougher in the UK. George Soros has written a lot about this and I have a lot of respect for him."

- On America: "I'm extremely optimistic because I think we have really great young people and I've always worked with young people."

Anand Desai's hedge fund firm Darsana Capital Partners has filed a 13G with the SEC regarding its stake in Spirit Aerosystems (SPR). Per the filing, Darsana now owns 5.4% of SPR with 7 million shares.

This is up from the 5.25 million shares they owned at the end of the second quarter. The filing was made due to activity on September 16th.

SPR has been a favorite among a few other hedge funds we cover as well: Hound Partners, Marble Arch Investments, Aravt Global, and Newtyn Management, among others.

About Darsana Capital

Prior to founding Darsana, Desai worked with Eric Mindich at Eton Park Capital. Darsana's most recent 13F filing showed $1.9 billion in assets but keep in mind that doesn't include international positions, or cash.

About Spirit Aerosystems

Per Google Finance, Spirit Aerosystems is "a non-original equipment manufacturer (OEM) aircraft parts designer and manufacturer of commercial aero-structures. The Company is a supplier of aero-structures to The Boeing Company (Boeing) and Airbus S.A.S (Airbus). The Company operates through three segments: Fuselage Systems, Propulsion Systems and Wing Systems. It is engaged in production, including the majority of the airframe content for the Boeing B737. It is also a content supplier of wing systems for the Airbus A320 family. It is a supplier for the Airbus A380 and Airbus A350 XWB (Xtra Wide-Body). Its products include Fuselage Systems, Propulsion Systems and Wing Systems. The Company offers spares and replacement parts for B737 Classic, B737NG, B747, B757, B767, B777, Rolls-Royce BR725, A320, A330, A340 and A380. Its Maintenance, Repair and Overhaul at repair stations provide complete on-site repair and overhaul to support MRO services for B747, B767, B777, B787 and Rolls-Royce BR725.."

Since 2009, over 25% of the companies featured in Boyar Research's Asset Analysis Focus
have achieved multi-bagger status within 3 years of publication. Over
the same period, the average stock Boyar profiled increased 73% compared
to the S&P 500's 45% gain.*

Average 3 Year Performance of Companies Profiled by Boyar Research

Some of Boyar Research's multi-baggers include:

Find
out what companies Boyar Research believes could be next by requesting
complimentary reports on three companies, exclusively for Market Folly
readers. Click here to receive the reports.

Since
1975 Boyar Research has been providing independent research utilizing a
business person's approach to stock market investing. They take a
company's financial statement and tear it apart, and then reconstruct it
in accordance with economic reality - as opposed to generally accepted
accounting principles. Their various publications provide in-depth
reports on companies they believe to be selling below their estimate of
intrinsic or private market value.

Past
performance is no guarantee of future results. These results are
unaudited. The results represent the 3 year performance from the date
of publication and takes into account spinouts and special dividends but
not regular dividends. These are the results of companies profiled in
all issues of Asset Analysis Focus excluding The Forgotten Forty.

Monday, September 26, 2016

Market strategist Jeff Saut of Raymond James has put out his latest piece entitled, "Schadenfreude." In it, he talks about his recent meeting with Steve Eisman.

Here's what Eisman is thinking these days, according to Saut: "Steve concluded that Europe is currently sick, the U.S. is likely destined for slow growth because there is not a big enough mortgage refi pipeline to boost the economy, and that Italy is in big trouble. Steve said to bea short seller you need to embrace 'Schadenfreude.'"

Eisman also walked Saut through the financial crisis, noting that for a crisis like that to happen, you need 3 things: too much leverage, a big asset class that blows up, and then large institutions holding most of the asset class that blows up.

Alex Klabin and Doug Silverman's hedge fund Senator Investment Group has filed a 13G with the SEC regarding shares of Comstock Resources (CRK). Per the filing, Senator now owns 7.32% of the company with 922,754 shares (including 93,500 shares issuable upon exercise of warrants).

This is a newly disclosed equity position for the firm as they did not own any at the end of the second quarter. The filing was made due to activity on September 13th.

Per Google Finance, Comstock Resources is "an energy company engaged in the acquisition, exploration, development and production of oil and natural gas in the United States. The Company operates in the segment of exploration and production of oil and natural gas. The Company's oil and gas operations are concentrated in Texas and Louisiana. Its operations are focused in two operating areas: East Texas/North Louisiana and South Texas. The Company's properties in the East Texas/North Louisiana region include approximately 80,660 acres in the Haynesville or Bossier shale formations. The Company's Eagleville field includes approximately 30,220 acres located in the oil window of the Eagle Ford shale in South Texas. The Company owns interests in over 1,575 producing oil and natural gas wells, and operates over 950 of these wells. The Company owns interests in over 20 wells in the Rosita field, located in Duval County, Texas."

John Paulson's hedge fund firm Paulson & Co has filed a Form 4 with the SEC regarding its stake in Synergy Pharmaceuticals (SGYP). Per the filing, Paulson sold over 3.47 million shares in total on September 16th and 19th at prices around $5.61.

After these transactions, Paulson & Co is left with exposure to SGYP of over 24.28 million shares.

A previously filed Form 3 with the SEC indicates that they had notional principal amount derivative agreements in place as well in the form of cash settled swaps representing share equivalents of 2.21 million shares with strikes ranging from $3.31 to $6.347 and expiration dates ranging from November 4th, 2016 to October 5th, 2017.

Per Google Finance, Synergy Pharmaceuticals is "a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine."

Disclaimer

The content provided within this website is property of MarketFolly.com and any views or opinions expressed herein are those solely of MarketFolly.com and do not represent that of any firm or institution. This website is for educational and/or entertainment purposes only. Use this information at your own risk. MarketFolly.com is not an investment advisor of any kind, so do not consider anything on this page to be legal, tax, or investment advice. MarketFolly.com is not responsible for any third party links or content. MarketFolly.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to amazon.com.